Dec 15 (Reuters) - Merck & Co Inc.'s drug to reverse the effects of muscle relaxants used during surgery has won U.S. approval. The Food and Drug Administration said on Tuesday it approved the drug, ...

Merck expects the FDA’s review to be completed in the first half of 2013. Sugammadex sodium injection is the company's investigational agent for the reversal of neuromuscular blockade (NMB) induced by ...

Merck & Co. Inc. MRK received disappointing news with the FDA cancelling a previously scheduled meeting with the Anesthetic and Analgesic Drug Products Advisory Committee on Mar 18 to consider the ...

WASHINGTON (Reuters) – U.S. health regulators need more time to review Merck & Co’s application to sell sugammadex, an injection designed to reverse the effects of muscle relaxants used during surgery ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of a meeting of the Anesthetic and ...

Therapeutic Hypothermia Study Heats Up Ethical Concerns The FDA has approved Bridion (sugammadex; Merck) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and ...

Merck & Co says the US Food and Drug Administration has accepted its resubmission of the anaesthesia compound sugammadex, which was rejected by the agency in 2008. Merck & Co says the US Food and Drug ...

Merck & Co's bid to get approval for sugammadex in the USA will have to wait a bit longer as regulators need more time to evaluate the anaesthesia compound. Merck & Co’s bid to get approval for ...

A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed (Reuters) - Merck & Co Inc.'s drug to reverse the effects of muscle ...